UK Regulatory Agency Approves Continued Enrollment in BioMarin Phase 1/2 Study of BMN 270 in Hemophilia A
13 oct. 2016 16h01 HE
|
BioMarin Pharmaceutical Inc.
Phase 1/2 Study Expected to Resume by End of 2016 Requirement for Prophylactic Corticosteroids Removed SAN RAFAEL, Calif., Oct. 13, 2016 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc....
BioMarin to Host Third Quarter 2016 Financial Results Conference Call and Webcast on Thursday, October 27 at 4:30pm ET
11 oct. 2016 08h30 HE
|
BioMarin Pharmaceutical Inc.
SAN RAFAEL, Calif., Oct. 11, 2016 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer of BioMarin, will...
BioMarin Reviews Status of Exon 51 Composition of Matter and Method of Use Patent Interference Cases against Sarepta Therapeutics
21 sept. 2016 08h53 HE
|
BioMarin Pharmaceutical Inc.
BioMarin to Seek Review of Ruling in Composition of Matter Patent Interference (No. 106,008) Patent Trial and Appeal Board Ruled in BioMarin’s Favor on Method of Use (MOU) Patent Interference (No....
BioMarin Announces EMA Validation of Brineura™ (Cerliponase Alfa) Marketing Authorization Application for Treatment of CLN2 Disease, a Form of Batten Disease
15 sept. 2016 08h37 HE
|
BioMarin Pharmaceutical Inc.
SAN RAFAEL, Calif., Sept. 15, 2016 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) announced today that the European Medicines Agency (EMA) validated the Marketing Authorization...
BioMarin Announces Update to Brineura™ (Cerliponase Alfa) Program for Treatment of CLN2 Disease, a Form of Batten Disease
06 sept. 2016 16h05 HE
|
BioMarin Pharmaceutical Inc.
Additional Data Submitted to BLA following FDA Request, PDUFA Action Date Extended to April 27, 2017 Additional 8 Months of Treatment (81-Week Data) Show Maintenance of Efficacy, Consistent with...
BioMarin to Attend Upcoming Investor Conferences
31 août 2016 08h30 HE
|
BioMarin Pharmaceutical Inc.
Citi’s 11th Annual Biotech Conference September 7 in Boston Robert W. Baird & Co. 2016 Global Healthcare Conference September 8 in New York Leerink Partners...
Forbes Ranks BioMarin 10th Most Innovative Company in the World
24 août 2016 09h53 HE
|
BioMarin Pharmaceutical Inc.
SAN RAFAEL, Calif., Aug. 24, 2016 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) announced today that it has been ranked 10th on Forbes magazine's 2016 list of the "World's Most...
BioMarin Announces Pricing of Public Offering of Common Stock
09 août 2016 09h00 HE
|
BioMarin Pharmaceutical Inc.
SAN RAFAEL, Calif., Aug. 09, 2016 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) announced today the pricing of an underwritten public offering of 7,500,000 shares of its common...
BioMarin Announces Public Offering of Common Stock
08 août 2016 16h32 HE
|
BioMarin Pharmaceutical Inc.
SAN RAFAEL, Calif., Aug. 08, 2016 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) announced today an offering, subject to market and other conditions, of 7,500,000 shares of its...
BioMarin Announces Second Quarter 2016 Financial Results
04 août 2016 16h03 HE
|
BioMarin Pharmaceutical Inc.
- Second Quarter 2016 Total BioMarin Revenue Increases 20.0% Y/Y to $300.1 million- Vimizim Net Product Revenue Increases 98.1% Y/Y and Contributes $106.8 million in the Second Quarter 2016; Vimizim...